Tvardi Therapeutics (NASDAQ:TVRD) Releases Earnings Results, Misses Estimates By $0.04 EPS

Tvardi Therapeutics (NASDAQ:TVRD) posted its quarterly earnings data on Friday. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04), FiscalAI reports.

Tvardi Therapeutics Trading Up 6.2%

NASDAQ TVRD traded up $0.11 on Friday, hitting $1.88. 284,960 shares of the stock traded hands, compared to its average volume of 977,574. The company has a market capitalization of $17.63 million, a P/E ratio of -0.60 and a beta of 0.39. The stock has a 50-day moving average of $2.51 and a 200 day moving average of $3.20. Tvardi Therapeutics has a twelve month low of $1.50 and a twelve month high of $43.65.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Tvardi Therapeutics to a “strong sell” rating in a report on Saturday, July 18th. HC Wainwright began coverage on shares of Tvardi Therapeutics in a research note on Monday, June 8th. They issued a “buy” rating and a $9.00 price objective for the company. Raymond James Financial upgraded shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a report on Wednesday, July 8th. BTIG Research reduced their target price on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Tvardi Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Institutional Trading of Tvardi Therapeutics

Hedge funds have recently bought and sold shares of the company. American Financial Group Inc. bought a new position in shares of Tvardi Therapeutics in the fourth quarter valued at approximately $962,000. Vestal Point Capital LP purchased a new stake in Tvardi Therapeutics during the third quarter valued at about $6,508,000. Geode Capital Management LLC purchased a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at approximately $2,617,000. BlackRock Inc. acquired a new position in Tvardi Therapeutics in the 2nd quarter worth approximately $181,000. Finally, Invesco Ltd. acquired a new stake in shares of Tvardi Therapeutics in the third quarter worth $3,219,000. 44.66% of the stock is currently owned by institutional investors.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.